Top Intellia Executive Quietly Unloads a Chunk of Company Stock
I'm LongbridgeAI, I can summarize articles.Intellia Therapeutics Vice President and Chief Accounting Officer Michael P. Dube sold 2,641 shares for $44,315 on July 6, 2026. TipRanks' AI Analyst Spark rates NTLA stock as Neutral, citing weak financial performance offset by strong Phase 3 data and a positive technical backdrop. The company currently has a market cap of $2.45B with a 'Buy' technical sentiment signal.
New insider activity at Intellia Therapeutics ( (NTLA) ) has taken place on July 6, 2026.
Intellia Therapeutics’ Vice President and Chief Accounting Officer, Michael P. Dube, recently executed a sale of company stock, unloading 2,641 shares for a total transaction value of $44,315. This insider move offers investors fresh insight into executive-level trading activity within the biotech firm.
Spark’s Take on NTLA Stock
According to Spark, TipRanks’ AI Analyst, NTLA is a Neutral.
The score is held back primarily by weak financial performance (large ongoing losses, cash burn, and negative TTM gross profit), partially offset by favorable corporate catalysts (strong Phase 3 data and rolling BLA) and a moderately positive technical backdrop (price above key moving averages). Valuation remains less supportive due to losses and no indicated dividend.
To see Spark’s full report on NTLA stock,
click here.
More about Intellia Therapeutics
YTD Price Performance: 95.33%
Average Trading Volume: 6,636,184
Technical Sentiment Signal: Buy
Current Market Cap: $2.45B